Effect of N-Vinyl-2-Pyrrolidone (NVP), a Bromodomain-Binding Small Chemical, on Osteoblast and Osteoclast Differentiation and Its Potential Application for Bone Regeneration.
Animals
Bone Diseases
/ drug therapy
Bone Morphogenetic Protein 2
/ agonists
Bone Regeneration
/ drug effects
Bone and Bones
/ pathology
Cell Differentiation
/ drug effects
Cell Survival
/ drug effects
Cells, Cultured
Core Binding Factor Alpha 1 Subunit
/ metabolism
Disease Models, Animal
Mice
Osteoblasts
/ cytology
Osteoclasts
/ cytology
Polylactic Acid-Polyglycolic Acid Copolymer
/ chemistry
Pyrrolidinones
/ chemistry
RANK Ligand
/ pharmacology
Rabbits
Smad1 Protein
/ metabolism
BMP2
bone regeneration
bromodomain inhibitor
osteoblast
osteoclast
small chemical
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Oct 2021
13 Oct 2021
Historique:
received:
13
08
2021
revised:
05
10
2021
accepted:
09
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The human skeleton is a dynamic and remarkably organized organ system that provides mechanical support and performs a variety of additional functions. Bone tissue undergoes constant remodeling; an essential process to adapt architecture/resistance to growth and mechanical needs, but also to repair fractures and micro-damages. Despite bone's ability to heal spontaneously, certain situations require an additional stimulation of bone regeneration, such as non-union fractures or after tumor resection. Among the growth factors used to increase bone regeneration, bone morphogenetic protein-2 (BMP2) is certainly the best described and studied. If clinically used in high quantities, BMP2 is associated with various adverse events, including fibrosis, overshooting bone formation, induction of inflammation and swelling. In previous studies, we have shown that it was possible to reduce BMP2 doses significantly, by increasing the response and sensitivity to it with small molecules called "BMP2 enhancers". In the present study, we investigated the effect of N-Vinyl-2-pyrrolidone (NVP) on osteoblast and osteoclast differentiation in vitro and guided bone regeneration in vivo. We showed that NVP increases BMP2-induced osteoblast differentiation and decreases RANKL-induced osteoclast differentiation in a dose-dependent manner. Moreover, in a rabbit calvarial defect model, the histomorphometric analysis revealed that bony bridging and bony regenerated area achieved with NVP-loaded poly (lactic-co-glycolic acid (PLGA) membranes were significantly higher compared to unloaded membranes. Taken together, our results suggest that NVP sensitizes BMP2-dependent pathways, enhances BMP2 effect, and inhibits osteoclast differentiation. Thus, NVP could prove useful as "osteopromotive substance" in situations where a high rate of bone regeneration is required, and in the management of bone diseases associated with excessive bone resorption, like osteoporosis.
Identifiants
pubmed: 34681710
pii: ijms222011052
doi: 10.3390/ijms222011052
pmc: PMC8541071
pii:
doi:
Substances chimiques
Bone Morphogenetic Protein 2
0
Core Binding Factor Alpha 1 Subunit
0
Pyrrolidinones
0
RANK Ligand
0
Runx2 protein, mouse
0
Smad1 Protein
0
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
N-vinyl-2-pyrrolidinone
76H9G81541
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Dev Cell. 2002 Dec;3(6):889-901
pubmed: 12479813
J Bone Miner Metab. 2021 Jul 11;:
pubmed: 34250565
Oncogene. 2002 Oct 17;21(47):7156-63
pubmed: 12370805
Periodontol 2000. 2014 Oct;66(1):13-40
pubmed: 25123759
J Dent Res. 2014 Jul;93(7):657-62
pubmed: 24799421
J Biol Chem. 2009 Jan 23;284(4):2584-92
pubmed: 19028686
Cell Rep. 2014 May 22;7(4):1009-19
pubmed: 24813887
Bone. 2009 Feb;44(2):199-207
pubmed: 18845279
Tissue Eng Part A. 2009 Oct;15(10):2955-63
pubmed: 19320543
Biomed Res Int. 2015;2015:421746
pubmed: 26247020
J Biomed Mater Res B Appl Biomater. 2019 Aug;107(6):1824-1832
pubmed: 30466196
J Biol Chem. 2011 Jul 8;286(27):24458-66
pubmed: 21613210
J Cell Biol. 1994 Dec;127(6 Pt 1):1755-66
pubmed: 7798324
Int J Mol Sci. 2018 Oct 25;19(11):
pubmed: 30366476
J Tissue Eng Regen Med. 2017 Feb;11(2):425-433
pubmed: 24919954
Int J Mol Sci. 2016 Sep 01;17(9):
pubmed: 27598138
J Biol Chem. 2004 Jun 18;279(25):26475-80
pubmed: 15073183
AAPS PharmSciTech. 2021 Jan 6;22(1):34
pubmed: 33404984
J Control Release. 2015 Apr 10;203:181-8
pubmed: 25697800
ChemMedChem. 2014 Mar;9(3):580-9
pubmed: 24000170
J Cell Mol Med. 2021 Oct;25(19):9089-9101
pubmed: 34490735
Immunol Rev. 2005 Dec;208:126-40
pubmed: 16313345
Clin Epigenetics. 2016 Apr 22;8:42
pubmed: 27110299
J Cell Biochem. 2005 Jun 1;95(3):518-28
pubmed: 15786511
Cancers (Basel). 2021 Jul 19;13(14):
pubmed: 34298819
Int Endod J. 2017 Mar;50(3):271-280
pubmed: 26913571
PLoS Genet. 2016 Sep 15;12(9):e1006272
pubmed: 27631103
Food Addit Contam. 1991 Mar-Apr;8(2):125-33
pubmed: 1868925
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
J Biol Chem. 2002 Oct 25;277(43):41147-56
pubmed: 12171919
Pharmaceutics. 2021 May 04;13(5):
pubmed: 34064408
Tissue Eng Part B Rev. 2016 Aug;22(4):284-97
pubmed: 26857241
J Cell Biochem. 2003 Dec 15;90(6):1287-98
pubmed: 14635200
Trends Pharmacol Sci. 2012 Mar;33(3):146-53
pubmed: 22277300
Bone. 2019 Oct;127:49-58
pubmed: 31152802
Bone. 2015 Sep;78:114-21
pubmed: 25959414
Materials (Basel). 2020 Jan 21;13(3):
pubmed: 31973011
Biochem Biophys Res Commun. 2009 Apr 3;381(2):247-52
pubmed: 19217886
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD003607
pubmed: 19821311
Genes Dis. 2014 Sep;1(1):87-105
pubmed: 25401122
Nat Commun. 2014 Mar 19;5:3511
pubmed: 24646477
J Am Chem Soc. 2005 Mar 2;127(8):2376-7
pubmed: 15724976
Can Anaesth Soc J. 1975 Jan;22(1):12-9
pubmed: 1109702
Sci Rep. 2017 Feb 08;7:42108
pubmed: 28176838